infection
Conditions
Interventions
group C:The doses were administered with sequence (1.0g, 2.0g, 0.25g, 0.5g) in four periods.
group A:The doses were administered with sequence (0.25g, 0.5g, 1.0g, 2.0g ) in four periods.
group B:The doses were administered with sequence (0.5g, 1.0g, 2.0g, 0.25g) in four periods.
group D:The doses were administered with sequence (2.0g, 0.25g, 0.5g, 1.0g) in four periods.
Sponsors
The first affiliated hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Healthy male and female volunteers; (2) Aged 18-40 years, with a group of subjects no younger than 10 years of age; (3) Body mass index (BMI) in the context of 19-25 kg/m2, [BMI= weight (kg)/height (m2)]; (4) Vonlunteers could communicate well with the researchers and comply with the requirements of the entire study; (5) Written informed consent was obtained from all subjects prior to enrolment.
Exclusion criteria
Exclusion criteria: (1) Participated in other clinical trials within three months; (2) Donated blood within one month, or plan to donate blood during the trial or within 1 month at the end of the trial; (3) The general examination and blood pressure, heart rate and respiratory conditions did not meet with standards; (4) subjects had a history or evidence of any clinically significant diseases by direct medical history questioning and physical examination; (5) Laboratory tests (blood and urine routine, liver and kidney function, ECG and HIV et. al) found hematological abnormalities, heart, liver and kidney dysfunction; (6) Women in menstrual period, pregnancy or lactation; (7) Subjects had a history of hypersensitivity,allergy, serious adverse drug reaction, especially to penicillin drugs; (8) Smoking, drinking or drug addiction prior to or during the study; (9) Unsuitable to participate in the trial considered by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCtn;Cmax;Tmax;t1/2z;fration of unchanged drug excreted in urin; | — |
Secondary
| Measure | Time frame |
|---|---|
| CLz/F;Vz/F;AUCss;Css_min;Cavg;fluctuation%;Accumulation_index; | — |
Countries
China
Contacts
Public ContactJianzhong Shen-tu
The first affiliated hospital, School of Medicine, Zhejiang University
Outcome results
None listed